Article Commentary: The Bal anz Study—Strengthening the Evidence for Neutral-PH Solutions Low in Glucose Degradation Products

Garg A.X. , Greene T. , Levin N.W. A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance. Nephrol Dial transplant 2008; 23: 52–5.

Piraino B. , Bernardini J. , Brown E. , Figueiredo A. , Johnson D.W. , Lye W.C. ISPD position statement on reducing the risks of peritoneal dialysis–related infections. Perit Dial Int 2011; 31: 614–30.

Ghali J.R. , Bannister K.M. , Brown F.G. , Rosman J.B. , Wiggins K.J. , Johnson D.W. Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients. Perit Dial Int 2011; 31: 651–62.

Brown M.C. , Simpson K. , Kerssens J.J. , Mactier R.A. on behalf of the Scottish Renal Registry. Peritoneal dialysis–associated peritonitis rates and outcomes in a national cohort are not improving in the post-millennium (2000 – 2007). Perit Dial Int 2011; 31: 639–50.

Boote J. , Baird W. , Beecroft C. Public involvement at the design stage of primary health research: a narrative review of case examples. Health Policy 2010; 95: 10–23.

Steenkamp R. , Castledine C. , Feest T. , Fogarty D. UK Renal Registry 13th Annual Report (December 2010): Chapter 2: UK RRT prevalence in 2009: national and centre-specific analyses. Nephron Clin Pract 2011; 119(Suppl 2): c27–52.

Wieslander A. , Linden T. , Kjellstrand P. Glucose degradation products in peritoneal dialysis fluids: how they can be avoided. Perit Dial Int 2001; 21(Suppl 3): S119–24.

Perl J. , Nessim S.J. , Bargman J.M. The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both? Kidney Int 2011; 79: 814–24.

Davies S.J. , Phillips L. , Naish P.F. , Russell G.I. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12: 1046–51.

Williams J.D. , Craig K.J. , Topley N. , Von Ruhland C. , Fallon M. , Newman G.R. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470–9.

Jörres A. Novel peritoneal dialysis solutions—what are the clinical implications? Blood Purif 2012; 33: 153–9.

Srivastava S. , Hildebrand S. , Fan S.L. Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival. Kidney Int 2011; 80: 986–91.

Johnson D.W. , Cho Y. , Brown F.G. Trials (and tribulations) of biocompatible peritoneal dialysis fluids. Perit Dial Int 2012; 32: 247–51.

Atkins D. , Best D. , Briss P.A. , Eccles M. , Falck-Ytter Y. , Flottorp S. on behalf of the GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.

Woodrow G. , Davies S. Renal Association Clinical Practice Guideline on peritoneal dialysis. Nephron Clin Pract 2011; 118(Suppl 1): c287–310.

Johnson D.W. , Brown F.G. , Clarke M. , Boudville N. , Elias T.J. , Foo M.W. on behalf of the balANZ Trial Investigators. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012; 23: 1097–107.

Johnson D.W. , Brown F.G. , Clarke M. , Boudville N. , Elias T.J. , Foo M.W. on behalf of the balANZ Trial Investigators. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrol Dial transplant 2012; [Epub ahead of print].

Davies S.J. , Brown E.A. , Frandsen N.E. , Rodrigues A.S. , Rodriguez– Carmona A. , Vychytil A. on behalf of the EAPOS group. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67: 1609–15.

Davies S.J. , Woodrow G. , Donovan K. , Plum J. , Williams P. , Johansson A.C. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol. 2003; 14: 2338–44.

Paniagua R. , Ventura M.D. , Avila-Díaz M. , Cisneros A. , Vicenté-Martínez M. , Furlong M.D. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int 2009; 29: 422–32.

Opatrna S. , Lysak D. , Trefil L. , Parker C. , Topley N. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate–based peritoneal dialysis solutions. Perit Dial Int 2012; 32: 37–44.

Slater M. Olympics cycling: marginal gains underpin Team GB dominance [Web article]. London, UK: BBC; 9 August 2012. [Available online at: http://www.bbc.co.uk/sport/0/olympics/19174302; accessed 29 August 2012]